Literature DB >> 32001105

Allosteric Regulation of BH3 Proteins in Bcl-xL Complexes Enables Switch-like Activation of Bax.

Christian Bogner1, Justin Kale2, Justin Pogmore2, Xiaoke Chi2, Aisha Shamas-Din3, Cécile Fradin4, Brian Leber5, David W Andrews6.   

Abstract

Current models of apoptosis regulation by the Bcl-2 family of proteins postulate that heterodimeric interactions between family members determine whether Bax and Bak are activated to trigger cell death. Thus, the relative abundance and binding affinities between pro- and anti-apoptotic proteins determines the outcome of these interactions. Examination of these interactions using purified mitochondria and liposomes with full-length recombinant proteins revealed that Bcl-xL inhibits apoptosis as a higher-order complex that binds multiple BH3 proteins. Allosteric regulation of this complex by the BH3 sensitizer Bad confers switch-like activity to the indirect activation of Bax. The BH3 activator cBid sequestered by Bcl-xL complexes changes from an inactive to an active form while bound to a Bcl-xL complex only when Bad is also bound. Bcl-xL complexes enable Bad to function as a non-competitive inhibitor of Bcl-xL and allosterically activate cBid, dramatically enhancing the pro-apoptotic potency of Bad.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bad; Bax; Bcl-2 family; Bcl-xL complexes; Bid; MOMP; allosteric activation; apoptosis; mitochondria; switch-like activation

Year:  2020        PMID: 32001105     DOI: 10.1016/j.molcel.2019.12.025

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  10 in total

1.  Overexpression of transmembrane protein 102 implicates poor prognosis and chemoresistance in epithelial ovarian carcinoma patients.

Authors:  Yi-Jou Tai; Cheng-Miao Ou; Ying-Cheng Chiang; Chi-Fang Chang; Chi-An Chen; Wen-Fang Cheng
Journal:  Am J Cancer Res       Date:  2022-09-15       Impact factor: 5.942

Review 2.  Reinventing the Penumbra - the Emerging Clockwork of a Multi-modal Mechanistic Paradigm.

Authors:  Jakob Walther; Elena Marie Kirsch; Lina Hellwig; Sarah S Schmerbeck; Paul M Holloway; Alastair M Buchan; Philipp Mergenthaler
Journal:  Transl Stroke Res       Date:  2022-10-11       Impact factor: 6.800

Review 3.  Structural Details of BH3 Motifs and BH3-Mediated Interactions: an Updated Perspective.

Authors:  Valentina Sora; Elena Papaleo
Journal:  Front Mol Biosci       Date:  2022-05-24

4.  Class IIa HDAC inhibitor TMP195 alleviates lipopolysaccharide-induced acute kidney injury.

Authors:  Wei Zhang; Yinjie Guan; George Bayliss; Shougang Zhuang
Journal:  Am J Physiol Renal Physiol       Date:  2020-10-05

Review 5.  Targeting of BCL-2 Family Members during Anticancer Treatment: A Necessary Compromise between Individual Cell and Ecosystemic Responses?

Authors:  Sophie Barillé-Nion; Steven Lohard; Philippe P Juin
Journal:  Biomolecules       Date:  2020-07-25

6.  Grape Seed Proanthocyanidin Extract Ameliorates Cardiac Remodelling After Myocardial Infarction Through PI3K/AKT Pathway in Mice.

Authors:  Yongxue Ruan; Qike Jin; Jingjing Zeng; Fangfang Ren; Zuoyi Xie; Kangting Ji; Lianpin Wu; Jingguo Wu; Lei Li
Journal:  Front Pharmacol       Date:  2020-12-04       Impact factor: 5.810

Review 7.  Apoptosis and Cell Proliferation Markers in Inflammatory-Fibroproliferative Diseases of the Vessel Wall (Review).

Authors:  E A Klimentova; I A Suchkov; A A Egorov; R E Kalinin
Journal:  Sovrem Tekhnologii Med       Date:  2020-08-27

8.  Bcl-xL acts as an inhibitor of IP3R channels, thereby antagonizing Ca2+-driven apoptosis.

Authors:  Nicolas Rosa; Hristina Ivanova; Larry E Wagner; Justin Kale; Rita La Rovere; Kirsten Welkenhuyzen; Nikolaos Louros; Spyridoula Karamanou; Victoria Shabardina; Irma Lemmens; Elien Vandermarliere; Kozo Hamada; Hideaki Ando; Frederic Rousseau; Joost Schymkowitz; Jan Tavernier; Katsuhiko Mikoshiba; Anastassios Economou; David W Andrews; Jan B Parys; David I Yule; Geert Bultynck
Journal:  Cell Death Differ       Date:  2021-11-08       Impact factor: 12.067

9.  Efficacy and specificity of inhibitors of BCL-2 family protein interactions assessed by affinity measurements in live cells.

Authors:  Elizabeth J Osterlund; Nehad Hirmiz; James M Pemberton; Adrien Nougarède; Qian Liu; Brian Leber; Qiyin Fang; David W Andrews
Journal:  Sci Adv       Date:  2022-04-20       Impact factor: 14.957

Review 10.  Aberrant Bcl-x splicing in cancer: from molecular mechanism to therapeutic modulation.

Authors:  Zhihui Dou; Dapeng Zhao; Xiaohua Chen; Caipeng Xu; Xiaodong Jin; Xuetian Zhang; Yupei Wang; Xiaodong Xie; Qiang Li; Cuixia Di; Hong Zhang
Journal:  J Exp Clin Cancer Res       Date:  2021-06-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.